PUMA BIOTECHNOLOGY, INC. Pre-Tax Income
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Pre-Tax Income of $8.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $8.24M, a 33.74% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$3.43M, a 204.90% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $17.11M, a 39.79% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $9.24M, a 55.15% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $35.78M, a 48.47% increase from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $24.10M, a 6.29% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $22.67M, a 4861.49% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $457.00K.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.24M 10-Q · filed 2026-08-06 | $4.82M 10-Q · filed 2026-08-06 | $21.93M derived: sum of 3 quarters · filed 2026-08-06 | $31.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.43M 10-Q · filed 2026-05-07 | $13.68M derived: sum of 2 quarters · filed 2026-05-07 | $22.92M derived: sum of 3 quarters · filed 2026-05-07 | $29.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.35M derived: sum of 2 quarters · filed 2026-02-26 | $32.52M derived: sum of 3 quarters · filed 2026-08-06 | $35.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.24M 10-Q · filed 2025-11-06 | $15.41M derived: sum of 2 quarters · filed 2026-08-06 | $18.68M 10-Q · filed 2025-11-06 | $30.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.17M 10-Q · filed 2026-08-06 | $9.43M 10-Q · filed 2026-08-06 | $21.67M derived: sum of 3 quarters · filed 2026-08-06 | $42.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.27M 10-Q · filed 2026-05-07 | $15.51M derived: sum of 2 quarters · filed 2026-05-07 | $36.11M derived: sum of 3 quarters · filed 2026-05-07 | $31.96M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.85M derived: sum of 2 quarters · filed 2026-02-26 | $28.70M derived: sum of 3 quarters · filed 2026-02-26 | $24.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $20.61M 10-Q · filed 2025-11-06 | $16.46M derived: sum of 2 quarters · filed 2025-11-06 | $11.86M 10-Q · filed 2025-11-06 | $24.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$4.15M 10-Q · filed 2025-08-07 | -$8.75M 10-Q · filed 2025-08-07 | $4.06M derived: sum of 3 quarters · filed 2026-02-26 | $10.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$4.59M 10-Q · filed 2025-05-08 | $8.21M derived: sum of 2 quarters · filed 2026-02-26 | $14.22M derived: sum of 3 quarters · filed 2026-02-26 | $16.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $12.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.81M derived: sum of 2 quarters · filed 2026-02-26 | $21.13M derived: sum of 3 quarters · filed 2026-02-26 | $22.67M 10-K · filed 2026-02-26 |
| 2023-09-30 | $6.01M 10-Q · filed 2024-11-07 | $8.32M derived: sum of 2 quarters · filed 2024-11-07 | $9.87M 10-Q · filed 2024-11-07 | $4.56M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.31M 10-Q · filed 2024-08-01 | $3.86M 10-Q · filed 2024-08-01 | -$1.45M derived: sum of 3 quarters · filed 2025-02-27 | -$1.74M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.55M 10-Q · filed 2024-05-02 | -$3.76M derived: sum of 2 quarters · filed 2025-02-27 | -$4.06M derived: sum of 3 quarters · filed 2025-02-27 | $5.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$5.61M derived: sum of 2 quarters · filed 2025-02-27 | $3.82M derived: sum of 3 quarters · filed 2025-02-27 | $457.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$293.00K 10-Q · filed 2023-11-02 | $9.13M derived: sum of 2 quarters · filed 2023-11-02 | $5.77M 10-Q · filed 2023-11-02 | $10.21M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $9.43M 10-Q · filed 2023-08-03 | $6.06M 10-Q · filed 2023-08-03 | $10.50M derived: sum of 3 quarters · filed 2024-02-29 | -$34.14M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$3.37M 10-Q · filed 2023-05-04 | $1.07M derived: sum of 2 quarters · filed 2024-02-29 | -$43.56M derived: sum of 3 quarters · filed 2024-02-29 | -$48.63M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$40.20M derived: sum of 2 quarters · filed 2024-02-29 | -$45.27M derived: sum of 3 quarters · filed 2024-02-29 | -$28.80M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$44.63M 10-Q · filed 2022-11-03 | -$49.70M derived: sum of 2 quarters · filed 2022-11-03 | -$33.24M 10-Q · filed 2022-11-03 | -$47.92M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | -$5.07M 10-Q · filed 2022-08-04 | $11.40M 10-Q · filed 2022-08-04 | -$3.29M derived: sum of 3 quarters · filed 2023-03-02 | -$34.75M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $16.57M 10-Q · filed 2022-05-05 | $1.78M derived: sum of 2 quarters · filed 2023-03-02 | -$29.68M derived: sum of 3 quarters · filed 2023-03-02 | -$26.29M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$46.25M derived: sum of 2 quarters · filed 2023-03-02 | -$42.85M derived: sum of 3 quarters · filed 2023-03-02 | -$59.79M 10-K · filed 2023-03-02 |
| 2020-09-30 | -$31.46M 10-Q · filed 2021-11-04 | -$28.07M derived: sum of 2 quarters · filed 2021-11-04 | -$45.00M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $3.40M 10-Q · filed 2021-08-05 | -$13.54M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$16.93M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$75.54M 10-K · filed 2022-03-03 | |||
| 2018-12-31 | -$113.56M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |